Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.7
4.6
Journals
Pharmaceuticals
Special Issues
Cell-Free DNA for the Management of Lymphoma
share announcement

Cell-Free DNA for the Management of Lymphoma

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Biopharmaceuticals".

Deadline for manuscript submissions: closed (28 January 2022) | Viewed by 15672

Special Issue Editor

Dr. Vincent Camus

E-Mail Website
Guest Editor
Department of Hematology and INSERM U1245, Centre Henri Becquerel, Rouen, France
Interests: circulating tumor DNA; hodgkin lymphoma; primary mediastinal B-cell lymphoma; liquid biopsy

Special Issue Information

Dear Colleagues,

The journal Pharmaceuticals is planning to publish a Special Issue covering the topic “Cell-free DNA for the Management of Lymphoma” and we are inviting you to contribute an article to this volume.

Lymphoma is an extremely heterogeneous disease with several distinct clinical, pathological, genetic, and molecular features. Routine diagnostic biopsy might not reflect the overall intratumoral genetic heterogeneity of lymphomas, contributing to insufficient somatic alteration detection that may be of clinical relevance as well as to prognostic and theranostic management. Testing fluid-based lymphoma-derived DNA represents the concept of liquid biopsy and may be regarded as a noninvasive dynamic way for lymphoma evolution assessment. The convenience of cell-free DNA (cfDNA) encompasses decreased risks associated with blood collection compared to tissue biopsy, the freedom to perform numerous sampling events over time, reasonable expense and possibly more lymphoma-representative sampling events than that offered by the spatial heterogeneity of tissue biopsy. cfDNA testing is currently useful as a prognostic biomarker at the diagnosis and during first-line therapy to complement positron emission tomography (PET) but may also help the diagnosis.

In the present Special Issue, we would like you to share your contributions to the advances and opportunities in this booming field of cfDNA tools. We also wish to assess situations where cfDNA monitoring might show promising progress toward wider acceptance in lymphoma management and discuss practical concerns that remain to be explored.

Dr. Vincent Camus
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Cell-free DNA
  • Circulating tumor DNA
  • Lymphoma
  • Precision medicine
  • Liquid biopsy

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

10 pages, 557 KiB  
Review
How to Obtain a High Quality ctDNA in Lymphoma Patients: Preanalytical Tips and Tricks
by Estelle Bourbon, Vincent Alcazer, Estelle Cheli, Sarah Huet and Pierre Sujobert
Pharmaceuticals 2021, 14(7), 617; https://0-doi-org.brum.beds.ac.uk/10.3390/ph14070617 - 26 Jun 2021
Cited by 6 | Viewed by 2534
Abstract
The analysis of circulating tumor DNA (ctDNA) released by tumor cells holds great promise for patients with lymphoma, to refine the diagnostic procedure, clarify the prognosis, monitor the response to treatment, and detect relapses earlier. One of the main challenges of the coming [...] Read more.
The analysis of circulating tumor DNA (ctDNA) released by tumor cells holds great promise for patients with lymphoma, to refine the diagnostic procedure, clarify the prognosis, monitor the response to treatment, and detect relapses earlier. One of the main challenges of the coming years is to adapt techniques from highly specialized translational teams to routine laboratories as this requires a careful technical and clinical validation, and we have to achieve this as fast as possible to transform a promising biomarker into a routine analysis to have a direct consequence on patient care. Whatever the analytical technology used, the prerequisite is to obtain high yields of ctDNA of optimal quality. In this review, we propose a step-by-step description of the preanalytical process to obtain high-quality ctDNA, emphasizing the technical choices that need to be made and the experimental data that can support these choices. Full article
(This article belongs to the Special Issue Cell-Free DNA for the Management of Lymphoma)
►▼ Show Figures

Figure 1

20 pages, 810 KiB  
Review
cfDNA Sequencing: Technological Approaches and Bioinformatic Issues
by Elodie Bohers, Pierre-Julien Viailly and Fabrice Jardin
Pharmaceuticals 2021, 14(6), 596; https://0-doi-org.brum.beds.ac.uk/10.3390/ph14060596 - 21 Jun 2021
Cited by 29 | Viewed by 9531
Abstract
In the era of precision medicine, it is crucial to identify molecular alterations that will guide the therapeutic management of patients. In this context, circulating tumoral DNA (ctDNA) released by the tumor in body fluids, like blood, and carrying its molecular characteristics is [...] Read more.
In the era of precision medicine, it is crucial to identify molecular alterations that will guide the therapeutic management of patients. In this context, circulating tumoral DNA (ctDNA) released by the tumor in body fluids, like blood, and carrying its molecular characteristics is becoming a powerful biomarker for non-invasive detection and monitoring of cancer. Major recent technological advances, especially in terms of sequencing, have made possible its analysis, the challenge still being its reliable early detection. Different parameters, from the pre-analytical phase to the choice of sequencing technology and bioinformatic tools can influence the sensitivity of ctDNA detection. Full article
(This article belongs to the Special Issue Cell-Free DNA for the Management of Lymphoma)
►▼ Show Figures

Figure 1

15 pages, 725 KiB  
Review
Cell-Free DNA for the Management of Classical Hodgkin Lymphoma
by Vincent Camus and Fabrice Jardin
Pharmaceuticals 2021, 14(3), 207; https://0-doi-org.brum.beds.ac.uk/10.3390/ph14030207 - 02 Mar 2021
Cited by 10 | Viewed by 2979
Abstract
Cell-free DNA (cfDNA) testing, is an emerging “liquid biopsy” tool for noninvasive lymphoma detection, and an increased amount of data are now available to use this technique with accuracy, especially in classical Hodgkin lymphoma (cHL). The advantages of cfDNA include simplicity of repeated [...] Read more.
Cell-free DNA (cfDNA) testing, is an emerging “liquid biopsy” tool for noninvasive lymphoma detection, and an increased amount of data are now available to use this technique with accuracy, especially in classical Hodgkin lymphoma (cHL). The advantages of cfDNA include simplicity of repeated blood sample acquisition over time; dynamic, noninvasive, and quantitative analysis; fast turnover time; reasonable cost; and established consistency with results from tumor genomic DNA. cfDNA analysis offers an easy method for genotyping the overall molecular landscape of pediatric and adult cHL and may help in cases of diagnostic difficulties between cHL and other lymphomas. cfDNA levels are correlated with clinical, prognostic, and metabolic features, and may serve as a therapeutic response evaluation tool and as a minimal residual disease (MRD) biomarker in complement to positron emission tomography (PET). Indeed, cfDNA real-time monitoring by fast high-throughput techniques enables the prompt detection of refractory disease or may help to address PET residual hypermetabolic situations during or at the end of treatment. The major recent works presented and described here demonstrated the clinically meaningful applicability of cfDNA testing in diagnostic and theranostic settings, but also in disease risk assessment, therapeutic molecular response, and monitoring of cHL treatments. Full article
(This article belongs to the Special Issue Cell-Free DNA for the Management of Lymphoma)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop